Two clinical trials of CPI immunotherapy in patients with platinum-resistant recurrent ovarian cancer showed objective response rate of only 9.6% (12/25) for anti-PD-L1 and 9% (11/97) for anti-PD-1 [15, 40]. This evidence concerns the gene PDCD1 and ovarian carcinoma.